What changed today in Metabolic: 8 trial updates

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

1. New trial registered: BOLD (Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity)[1]
2. New trial registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After…[2]
3. New trial registered: Changes in Body Composition Following Pharmacological Treatment for Obesity.[3]
4. Results posted on ClinicalTrials.gov: STEP HFpEF DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes)[4]
5. New trial registered: WISPER (Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer)[5]
6. New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation[6]
7. Trial status changed to “Recruiting”: Hypothalamic GLP-1 Response in Healthy Weight and Obesity[7]
8. New trial registered: An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals[8]

Who this affects

• Weight-management clinics
• Med spas
• Pharmacists
• Prescribers
• Medical directors
• Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

Source file

1. [1]
   New trial registered: BOLD (Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

2. [2]
   New trial registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

3. [3]
   New trial registered: Changes in Body Composition Following Pharmacological Treatment for Obesity. (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

4. [4]
   Results posted on ClinicalTrials.gov: STEP HFpEF DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

5. [5]
   New trial registered: WISPER (Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

6. [6]
   New trial registered: ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

7. [7]
   Trial status changed to “Recruiting”: Hypothalamic GLP-1 Response in Healthy Weight and Obesity (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

8. [8]
   New trial registered: An Open Label Pilot Study Assessing the Impact of Chromium Picolinate Supplementation on Appetite and Cravings in Overweight Individuals (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Nov 1, 2026

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.